| # | Drug | Count |
|---|---|---|
| 0 | ACETAZOLAMIDE | 11 |
| 1 | ACETAZOLAMIDE SODIUM | 11 |
| 2 | FENTANYL | 7 |
| 3 | PREGABALIN | 7 |
| 4 | VENLAFAXINE | 7 |
| 5 | VENLAFAXINE HYDROCHLORIDE | 7 |
| 6 | TOPIRAMATE | 6 |
| 7 | OLMESARTAN MEDOXOMIL | 3 |
| 8 | TEBENTAFUSP | 3 |
| 9 | ACETAMINOPHEN | 2 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | TEBENTAFUSP | 3 | 0.0050 |
| 1 | ACETAZOLAMIDE SODIUM | 11 | 0.0018 |
| 2 | TOPIRAMATE | 6 | 0.0001 |
| 3 | OLMESARTAN MEDOXOMIL | 3 | 0.0001 |
| 4 | EMICIZUMAB | 1 | 0.0001 |
| 5 | TOFACITINIB CITRATE | 1 | 0.0001 |
| 6 | FENTANYL | 7 | 0.0001 |
| 7 | VENLAFAXINE HYDROCHLORIDE | 7 | 0.0001 |
| 8 | MELPHALAN HYDROCHLORIDE | 1 | 0.0000 |
| 9 | MESALAMINE | 1 | 0.0000 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Bispecific gp100 Peptide-HLA-directed CD3 T Cell Engager [EPC] | 3 | 0.0050 |
| 1 | Carbonic Anhydrase Inhibitor [EPC] | 11 | 0.0005 |
| 2 | Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC] | 1 | 0.0001 |
| 3 | Opioid Agonist [EPC] | 7 | 0.0000 |
| 4 | Complement Inhibitor [EPC] | 1 | 0.0000 |
| 5 | Integrin Receptor Antagonist [EPC] | 1 | 0.0000 |
| 6 | Purine Antimetabolite [EPC] | 1 | 0.0000 |
| 7 | Aminosalicylate [EPC] | 1 | 0.0000 |
| 8 | Interleukin-23 Antagonist [EPC] | 1 | 0.0000 |
| 9 | Calcium [EPC] | 1 | 0.0000 |